Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Nnaemeka IbehIan BaineLouella Fuentes RudonChristine Lomas-FrancisJeffrey S JhangPatricia GaldonConnie M WesthoffRandall W VelliquetteSuzanne A ArinsburgPublished in: Transfusion (2021)
Our in-house trypsin-based method enables pretransfusion testing of patients receiving DARA in an accurate and cost-effective manner without missing clinically significant alloantibodies. This presents an additional testing option where DTT use is undesirable.